{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:48:23Z","timestamp":1793162903484,"version":"4.5.0"},"reference-count":33,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T00:00:00Z","timestamp":1649808000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Osteosarcoma (OS) is an uncommon tumour that mainly affects bone in children and adolescents. The current treatment options of OS are of limited significance due to their immense side effects. In the present manuscript, we have developed a novel series of 1,2,3-triazole chalcone derivatives as potential agents against OS. The compounds were synthesized and evaluated for their PI3K and mTOR inhibitory activity using luminescent kinase assay, and Lance ultra assay, resp. The entire set of compounds showed significant to moderate inhibition of both kinases in the nanomolar range. The three most active compounds:\n                    <jats:bold>4e<\/jats:bold>\n                    (\n                    <jats:italic>N<\/jats:italic>\n                    -(4-(3-(1-(4-bromophenyl)-1\n                    <jats:italic>H<\/jats:italic>\n                    -1,2,3-triazol-4-yl)acryloyl)phenyl)-4-nitrobenzamide),\n                    <jats:bold>4f<\/jats:bold>\n                    (\n                    <jats:italic>N<\/jats:italic>\n                    -(4-(3-(1-(4-bromophenyl)-1\n                    <jats:italic>H<\/jats:italic>\n                    -1,2,3-triazol-4-yl)acryloyl)phenyl)-4-chlorobenzamide) and\n                    <jats:bold>4g<\/jats:bold>\n                    (4-bromo-\n                    <jats:italic>N<\/jats:italic>\n                    -(4-(3-(1-(4-bromophenyl)-1\n                    <jats:italic>H-<\/jats:italic>\n                    1,2,3-triazol-4-yl)acryloyl)phenyl)benzamide), were evaluated for anticancer activity against human OS cancer cell line (MG-63), liver cancer cell line (HepG2), lung cancer cell line (A549) and cervical cancer (HeLa), using MTT assay. Among the tested series, compound\n                    <jats:bold>4e<\/jats:bold>\n                    showed a better inhibitory profile than gedatolisib against PI3K and was approximately comparable to that of gedatolisib against mTOR. The most significant inhibitory activity was observed for compound\n                    <jats:bold>4e<\/jats:bold>\n                    against all cell lines (MG-63, HepG2, A549 and HeLa), still somewhat lower to comparable to that of gedatolisib, but with the highest potency against MG-63 cells. Compound\n                    <jats:bold>4e<\/jats:bold>\n                    was further tested for anti-cancer activity against other OS cells and showed to be equipo-tent to gedatolisib against U2OS and Saos-2 cells. Moreover, it was also found non-toxic to normal cells (BEAS-2B and MCF 10A). The effect of compound\n                    <jats:bold>4e<\/jats:bold>\n                    was further determined on apoptosis of Saos-2 cells by Annexin-PI assay, where it significantly amplified the percentage of apoptotic cells. Novel 1,2,3-triazole chalcone derivatives are potential agents against OS.\n                  <\/jats:p>","DOI":"10.2478\/acph-2022-0026","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T13:46:47Z","timestamp":1649857607000},"page":"389-402","source":"Crossref","is-referenced-by-count":6,"title":["Design and development of novel 1,2,3-triazole chalcone derivatives as potential anti-osteosarcoma agents\n                    <i>via<\/i>\n                    inhibition of PI3K\/Akt\/mTOR signalling pathway"],"prefix":"10.2478","volume":"72","author":[{"given":"Qing","family":"Su","sequence":"first","affiliation":[{"name":"Department of Orthopedic Oncology , Yantai Shan Hospital , Yantai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baolin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Orthopedics The Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou , , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhoubin","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Joint Surgery , Shandong Provincial Hospital Affiliated to Shandong First Medical University , Jinan , , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziling","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery , Shanghai Jiao Tong University Affiliated Sixth People\u2019s Hospital Shanghai , , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2022,4,13]]},"reference":[{"key":"2026051108194168334_j_acph-2022-0026_ref_001","doi-asserted-by":"crossref","unstructured":"1. A. Misaghi, A. Goldin, M. Awad and A. A. Kulidjian, Osteosarcoma: A comprehensive review, SICOT J. 4 (2018) Article ID 12; https:\/\/doi.org\/10.1051\/sicotj\/201702810.1051\/sicotj\/2017028589044829629690","DOI":"10.1051\/sicotj\/2017028"},{"key":"2026051108194168334_j_acph-2022-0026_ref_002","doi-asserted-by":"crossref","unstructured":"2. S. S. Bielack, S. Hecker-Nolting, C. Blattmann and L. Kager, Advances in the management of osteosarcoma, F1000Res. 5 (2016) Article ID 2767; https:\/\/doi.org\/10.12688\/f1000research.9465.110.12688\/f1000research.9465.1513008227990273","DOI":"10.12688\/f1000research.9465.1"},{"key":"2026051108194168334_j_acph-2022-0026_ref_003","doi-asserted-by":"crossref","unstructured":"3. R. A. Durfee, M. Mohammed and H. H. Luu, Review of osteosarcoma and current management, Rheumatol. Ther. 3 (2016) 221\u2013243; https:\/\/doi.org\/10.1007\/s40744-016-0046-y10.1007\/s40744-016-0046-y512797027761754","DOI":"10.1007\/s40744-016-0046-y"},{"key":"2026051108194168334_j_acph-2022-0026_ref_004","doi-asserted-by":"crossref","unstructured":"4. J. Zhang, P. L. Yang and N. S. Gray, Targeting cancer with small molecule kinase inhibitors, Nat. Rev. Cancer 9 (2009) 28\u201339; https:\/\/doi.org\/10.1038\/nrc255910.1038\/nrc255919104514","DOI":"10.1038\/nrc2559"},{"key":"2026051108194168334_j_acph-2022-0026_ref_005","doi-asserted-by":"crossref","unstructured":"5. T. G. Davies, J. Bentley, C. E. Arris, F. T. Boyle, N. J. Curtin, J. A. Endicott, A. E. Gibson, B. T. Golding, R. J. Griffin, I. R. Hardcastle, P. Jewsbury, L. N. Johnson, V. Mesguiche, D. R. Newell, M. E. M. Noble, J. A. Tucker, L. Wang and H. J. Whitfield, Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor, Nat. Struct. Biol. 9 (2002) 745\u2013749; https:\/\/doi.org\/10.1038\/nsb84210.1038\/nsb84212244298","DOI":"10.1038\/nsb842"},{"key":"2026051108194168334_j_acph-2022-0026_ref_006","doi-asserted-by":"crossref","unstructured":"6. J. K. Srivastava, G. G. Pillai, H. R. Bhat, A. Verma and U. P. Singh, Design and discovery of novel monastrol-1,3,5-triazines as potent anti-breast cancer agent via attenuating epidermal growth factor receptor tyrosine kinase, Sci. Rep. 7 (2017) Article ID 5851 (18 pages); https:\/\/doi.org\/10.1038\/s41598-017-05934-510.1038\/s41598-017-05934-5551756228724908","DOI":"10.1038\/s41598-017-05934-5"},{"key":"2026051108194168334_j_acph-2022-0026_ref_007","doi-asserted-by":"crossref","unstructured":"7. L. Jakobsson, J. Kreuger, K. Holmborn, L. Lundin, I. Eriksson, L. Kjell\u00e9n and L. Claesson-Welsh, Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis, Dev. Cell 10 (2006) 625\u2013634; https:\/\/doi.org\/10.1016\/j.devcel.2006.03.00910.1016\/j.devcel.2006.03.00916678777","DOI":"10.1016\/j.devcel.2006.03.009"},{"key":"2026051108194168334_j_acph-2022-0026_ref_008","doi-asserted-by":"crossref","unstructured":"8. G. Garg, A. Khandelwal and B. S. J. Blagg, Chapter three \u2013 Anticancer inhibitors of Hsp90 function: Beyond the usual suspects, Adv. Cancer Res. 129 (2016) 51\u201388; https:\/\/doi.org\/10.1016\/bs.acr.2015.12.00110.1016\/bs.acr.2015.12.001589242226916001","DOI":"10.1016\/bs.acr.2015.12.001"},{"key":"2026051108194168334_j_acph-2022-0026_ref_009","doi-asserted-by":"crossref","unstructured":"9. H. P\u00f3pulo, J. M. Lopes and P. Soares, The mTOR signalling pathway in human cancer, Int. J. Mol. Sci. 13(2) (2012) 1886\u20131918; https:\/\/doi.org\/10.3390\/ijms1302188610.3390\/ijms13021886329199922408430","DOI":"10.3390\/ijms13021886"},{"key":"2026051108194168334_j_acph-2022-0026_ref_010","doi-asserted-by":"crossref","unstructured":"10. U. P. Singh, J. K. Srivastava and H. R. Bhat, 161P Discovery of novel 1,3,5-triazine-thiourea based dual PI3K\/mTOR inhibitor against non-small cell lung cancer (NSCLC), Ann. Oncol. 27(Suppl. 9) (2016) ix50; https:\/\/doi.org\/10.1093\/annonc\/mdw579.01310.1093\/annonc\/mdw579.013","DOI":"10.1016\/S0923-7534(21)00319-7"},{"key":"2026051108194168334_j_acph-2022-0026_ref_011","doi-asserted-by":"crossref","unstructured":"11. N. Hay, The Akt-mTOR tango and its relevance to cancer, Cancer Cell 8(3) (2005) 179\u2013183; https:\/\/doi.org\/10.1016\/j.ccr.2005.08.00810.1016\/j.ccr.2005.08.00816169463","DOI":"10.1016\/j.ccr.2005.08.008"},{"key":"2026051108194168334_j_acph-2022-0026_ref_012","doi-asserted-by":"crossref","unstructured":"12. L. Zhang, J. Wu, M. T. Ling, L. Zhao and K.-N. Zhao, The role of the PI3K\/Akt\/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses, Mol. Cancer 14 (2015) Article ID 87 (13 pages); https:\/\/doi.org\/10.1186\/s12943-015-0361-x10.1186\/s12943-015-0361-x449856026022660","DOI":"10.1186\/s12943-015-0361-x"},{"key":"2026051108194168334_j_acph-2022-0026_ref_013","doi-asserted-by":"crossref","unstructured":"13. X. Liu, Y. Xu, Q. Zhou, M. Chen, Y. Zhang, H. Liang, J. Zhao, W. Zhong and M. Wang, PI3K in cancer: its structure, activation modes and role in shaping tumor microenvironment, Future Oncol.14(7) (2017) 665\u2013674; https:\/\/doi.org\/10.2217\/fon-2017-058810.2217\/fon-2017-058829219001","DOI":"10.2217\/fon-2017-0588"},{"key":"2026051108194168334_j_acph-2022-0026_ref_014","doi-asserted-by":"crossref","unstructured":"14. B. Wang and J. Li, Piceatannol suppresses the proliferation and induced apoptosis of osteosarcoma cells through PI3K\/AKT\/MTOR pathway, Cancer Manag. Res. 12 (2020) 2631\u20132640; https:\/\/doi.org\/10.2147\/CMAR.S23817310.2147\/CMAR.S238173718270332368141","DOI":"10.2147\/CMAR.S238173"},{"key":"2026051108194168334_j_acph-2022-0026_ref_015","doi-asserted-by":"crossref","unstructured":"15. Y. Zhang, Q. Weng, J. Han and J. Chen, Alantolactone suppresses human osteosarcoma through the PI3K\/AKT signaling pathway, Mol. Med. Rep. 21(2) (2020) 675\u2013684; https:\/\/doi.org\/10.3892\/mmr.2019.1088210.3892\/mmr.2019.10882694791431974628","DOI":"10.3892\/mmr.2019.10882"},{"key":"2026051108194168334_j_acph-2022-0026_ref_016","doi-asserted-by":"crossref","unstructured":"16. M. W. Bishop and K. A. Janeway, Emerging concepts for PI3K\/mTOR inhibition as a potential treatment for osteosarcoma, F1000Res. 5 (2016) Article ID 1590 (6 pages); https:\/\/doi.org\/10.12688\/F1000RESEARCH.8228.110.12688\/f1000research.8228.1493781727441088","DOI":"10.12688\/f1000research.8228.1"},{"key":"2026051108194168334_j_acph-2022-0026_ref_017","doi-asserted-by":"crossref","unstructured":"17. J. A. Perry, A. Kiezun, P. Tonzi, E. M. Van Allen, S. L. Carter, S. C. Baca, G. S. Cowley, A. S. Bhatt, E. Rheinbay, C. S. Pedamallu, E. Helman, A. Taylor-Weiner, A. McKenna, D. S. DeLuca, M. S. Lawrence, L. Ambrogio, C. Sougnez, A. Sivachenko, L. D. Walensky, N. Wagle, J. Mora, C. de Torres, C. Lavarino, S. Dos Santos Aguiar, J. A. Yunes, S. R. Brandalise, G. E. Mercado-Celis, J. Melendez-Zajgla, R. C\u00e1rdenas-Card\u00f3s, L. Velasco-Hidalgo, C. W. M. Roberts, L. A. Garraway, C. Rodriguez-Galindo, S. B. Gabriel, E. S. Lander, T. R. Golub, S. H. Orkin, G. Getz and K. A. Janeway, Complementary genomic approaches highlight the PI3K\/mTOR pathway as a common vulnerability in osteosarcoma, Proc. Natl. Acad. Sci. USA 111(51) (2014) E5564\u2013E5573; https:\/\/doi.org\/10.1073\/pnas.141926011110.1073\/pnas.1419260111428063025512523","DOI":"10.1073\/pnas.1419260111"},{"key":"2026051108194168334_j_acph-2022-0026_ref_018","doi-asserted-by":"crossref","unstructured":"18. M. Penel-Page, I. Ray-Coquard, J. Larcade, M. Girodet, L. Bouclier, M. Rogasik, N. Corradini, N. Entz-Werle, L. Brugieres, J. Domont, C. Lervat, S. Piperno-Neumann, H. Pacquement, J.-O. Bay, J.-C. Gentet, A. Thyss, L. Chaigneau, B. Narciso, H. Cornille, J.-Y. Blay and P. Marec-B\u00e9rard, Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC\u2019S (Observatoire de l\u2019Utilisation des Th\u00e9rapies Cibl\u00e9es dans les Sarcomes), BMC Cancer 15 (2015) Article ID 854 (9 pages); https:\/\/doi.org\/10.1186\/s12885-015-1894-510.1186\/s12885-015-1894-5463596826541413","DOI":"10.1186\/s12885-015-1894-5"},{"key":"2026051108194168334_j_acph-2022-0026_ref_019","doi-asserted-by":"crossref","unstructured":"19. K. Singh, A. Gangrade, A. Jana, B. B. Mandal and N. Das, Design, synthesis, characterization, and antiproliferative activity of organoplatinum compounds bearing a 1,2,3-triazole ring, ACS Omega 4 (2019) 835\u2013841; https:\/\/doi.org\/10.1021\/acsomega.8b0284910.1021\/acsomega.8b02849","DOI":"10.1021\/acsomega.8b02849"},{"key":"2026051108194168334_j_acph-2022-0026_ref_020","doi-asserted-by":"crossref","unstructured":"20. N. S. Goud, V. Pooladanda, G. S. Mahammad, P. Jakkula, S. Gatreddi, I. A. Qureshi, R. Alvala, C. Godugu and M. Alvala, Synthesis and biological evaluation of morpholines linked coumarintriazole hybrids as anticancer agents, Chem. Biol. Drug Des. 94(5) (2019) 1919\u20131929; https:\/\/doi.org\/10.1111\/cbdd.1357810.1111\/cbdd.1357831169963","DOI":"10.1111\/cbdd.13578"},{"key":"2026051108194168334_j_acph-2022-0026_ref_021","doi-asserted-by":"crossref","unstructured":"21. G. Silva, M. Marins, A. L. Fachin, S.-H. Lee and S. J. Baek, Anti-cancer activity of trans-chalcone in osteosarcoma: Involvement of Sp1 and p53, Mol. Carcinog. 55(10) (2016) 1438\u20131448; https:\/\/doi.org\/10.1002\/mc.2238610.1002\/mc.2238626294168","DOI":"10.1002\/mc.22386"},{"key":"2026051108194168334_j_acph-2022-0026_ref_022","doi-asserted-by":"crossref","unstructured":"22. T. Ji, C. Lin, L. S. Krill, R. Eskander, Y. Guo, X. Zi and B. H. Hoang, Flavokawain B, a kava chalcone, inhibits growth of human osteosarcoma cells through G2\/M cell cycle arrest and apoptosis, Mol. Cancer 12 (2013) Article ID 55 (11 pages); https:\/\/doi.org\/10.1186\/1476-4598-12-5510.1186\/1476-4598-12-55368160323764122","DOI":"10.1186\/1476-4598-12-55"},{"key":"2026051108194168334_j_acph-2022-0026_ref_023","doi-asserted-by":"crossref","unstructured":"23. D. Dheer, V. Singh and R. Shankar, Medicinal attributes of 1,2,3-triazoles: Current developments, Bioorg. Chem. 71 (2017) 30\u201354; https:\/\/doi.org\/10.1016\/j.bioorg.2017.01.01010.1016\/j.bioorg.2017.01.01028126288","DOI":"10.1016\/j.bioorg.2017.01.010"},{"key":"2026051108194168334_j_acph-2022-0026_ref_024","doi-asserted-by":"crossref","unstructured":"24. K. Bozorov, J. Zhao and H. A. Aisa, 1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: A recent overview, Bioorg. Med. Chem. 27(16) (2019) 3511\u20133531; https:\/\/doi.org\/10.1016\/j.bmc.2019.07.00510.1016\/j.bmc.2019.07.005718547131300317","DOI":"10.1016\/j.bmc.2019.07.005"},{"key":"2026051108194168334_j_acph-2022-0026_ref_025","doi-asserted-by":"crossref","unstructured":"25. Z. Xu, S.-J. Zhao and Y. Liu, 1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships, Eur. J. Med. Chem. 183 (2019) Article ID 111700; https:\/\/doi.org\/10.1016\/j.ejmech.2019.11170010.1016\/j.ejmech.2019.11170031546197","DOI":"10.1016\/j.ejmech.2019.111700"},{"key":"2026051108194168334_j_acph-2022-0026_ref_026","doi-asserted-by":"crossref","unstructured":"26. S. Vanaparthi, R. Bantu, N. Jain, S. Janardhan and L. Nagarapu, Synthesis and anti-proliferative activity of a novel 1,2,3-triazole tethered chalcone acetamide derivatives, Bioorg. Med. Chem. Lett. 30(16) (2020) Article ID 127304.; https:\/\/doi.org\/10.1016\/j.bmcl.2020.12730410.1016\/j.bmcl.2020.12730432631524","DOI":"10.1016\/j.bmcl.2020.127304"},{"key":"2026051108194168334_j_acph-2022-0026_ref_027","doi-asserted-by":"crossref","unstructured":"27. S. Li, J. Wawrzyniak, Y. Queneau and L. Soul\u00e8re, 2-Substituted aniline as a simple scaffold for LuxR-regulated QS modulation, Molecules 22(12) (2017) Article ID 2090 (10 pages); https:\/\/doi.org\/10.3390\/molecules2212209010.3390\/molecules22122090614992229186042","DOI":"10.3390\/molecules22122090"},{"key":"2026051108194168334_j_acph-2022-0026_ref_028","doi-asserted-by":"crossref","unstructured":"28. J. Hu, Y. Zhang, N. Tang, Y. Lu, P. Guo and Z. Huang, Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K\/mTOR, Bioorg. Med. Chem. 32 (2021) Article ID 115997; https:\/\/doi.org\/10.1016\/j.bmc.2021.11599710.1016\/j.bmc.2021.11599733440319","DOI":"10.1016\/j.bmc.2021.115997"},{"key":"2026051108194168334_j_acph-2022-0026_ref_029","doi-asserted-by":"crossref","unstructured":"29. T.-T. Wu, Q.-Q. Guo, Z.-L. Chen, L.-L. Wang, Y. Du, R. Chen, Y.-H. Mao, S.-G. Yang, J. Huang, J.-T. Wang, L. Wang, L. Tang and J. Q. Zhang, Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K\/mTOR inhibitors, Eur. J. Med. Chem. 204 (2020) Article ID 112637; https:\/\/doi.org\/10.1016\/j.ejmech.2020.11263710.1016\/j.ejmech.2020.11263732717477","DOI":"10.1016\/j.ejmech.2020.112637"},{"key":"2026051108194168334_j_acph-2022-0026_ref_030","doi-asserted-by":"crossref","unstructured":"30. C.-H. R. Or, H.-L. Su, W.-C. Lee, S.-Y. Yang, C. Ho and C.-C. Chang, Diphenhydramine induces melanoma cell apoptosis by suppressing STAT3\/MCL-1 survival signaling and retards B16-F10 melanoma growth in vivo, Oncol. Rep. 36(6) (2016) 3465\u20133471; https:\/\/doi.org\/10.3892\/or.2016.520110.3892\/or.2016.520127779705","DOI":"10.3892\/or.2016.5201"},{"key":"2026051108194168334_j_acph-2022-0026_ref_031","doi-asserted-by":"crossref","unstructured":"31. H. F. Ashour, L. A. Abou-zeid, M. A.-A. El-Sayed and K. B. Selim, 1,2,3-Triazole-chalcone hybrids: Synthesis, in vitro cytotoxic activity and mechanistic investigation of apoptosis induction in multiple myeloma RPMI-8226, Eur. J. Med. Chem. 189 (2020) Article ID 112062; https:\/\/doi.org\/10.1016\/j.ejmech.2020.11206210.1016\/j.ejmech.2020.11206231986406","DOI":"10.1016\/j.ejmech.2020.112062"},{"key":"2026051108194168334_j_acph-2022-0026_ref_032","doi-asserted-by":"crossref","unstructured":"32. D.-J. Fu, S.-Y. Zhang, Y.-C. Liu, X.-X. Yue, J.-J. Liu, J. Song, R.-H. Zhao, F. Li, H.-H. Sun, Y.-B. Zhang and H.-M. Liu, Design, synthesis and antiproliferative activity studies of 1,2,3-triazole-chalcones, MedChemComm 7(8) (2016) 1664\u20131671; https:\/\/doi.org\/10.1039\/c6md00169f10.1039\/C6MD00169F","DOI":"10.1039\/C6MD00169F"},{"key":"2026051108194168334_j_acph-2022-0026_ref_033","doi-asserted-by":"crossref","unstructured":"33. S.-Y. Zhang, D.-J. Fu, X.-X. Yue, Y.-C. Liu, J. Song, H.-H. Sun, H.-M. Liu and Y.-B. Zhang, Design, synthesis and structure-activity relationships of novel chalcone-1,2,3-triazole-azole derivates as antiproliferative agents, Molecules 21(5) (2016) Article ID 653 (13 pages); https:\/\/doi.org\/10.3390\/molecules2105065310.3390\/molecules21050653627451727213317","DOI":"10.3390\/molecules21050653"}],"container-title":["Acta Pharmaceutica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/acph-2022-0026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T08:29:19Z","timestamp":1778488159000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/acph-2022-0026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,13]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,4,13]]},"published-print":{"date-parts":[[2022,9,1]]}},"alternative-id":["10.2478\/acph-2022-0026"],"URL":"https:\/\/doi.org\/10.2478\/acph-2022-0026","relation":{},"ISSN":["1846-9558"],"issn-type":[{"value":"1846-9558","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,13]]}}}